市场本周走势分化，沪指涨0.4%，全市场量能较上周有所放大，其中两个交易日成交额突破2万亿，板块题材上，可控核 聚变、CPO、光刻机、商业航天、贵金属等板块涨幅居前，磷化工、房地产、中药、乳业等板块调整；港股本周整体调 整，大型科技股涨跌互现，医药股跌幅居前。本周，沪深300指数下跌0.1%，中证A500指数上涨0.3%，创业板指数上涨 2.7%，上证科创板50成份指数上涨1.7%，恒生中国企业指数下跌1.3%。 | | 沪深300指数 / 中证A500指数 | | 创业板 | 上证科创板 | 恒生中国 | | --- | --- | --- | --- | --- | --- | | | | | 指数 | 50成份指数 | 企业指数 | | 指数分类 | A股大盘宽基 | | 创业板 | 科创板 | 港股 | | | | | 大盘宽基 | 大盘宽基 | 大盘宽基 | | 本周涨跌幅 | -0. 1% | 0. 3% | 2.7% | 1.7% | -1. 3% | | 指数滚动 市盈率 | 13.9倍 | 16. 4倍 | 40. 4倍 | 149.8倍 | 10. 4倍 | | 滚动市盘率 分位 | 60 ...

（来源：黄埔视野） 最近黄埔楼市，热度爆表！ 截至11月30日，黄埔区各改造项目已通过房票认购商品房超过5000套，面积超50万平方米，金额约88亿元。 88亿的入场，意味着大量的旧改权益正在加速兑现。 买多大？买哪里？怎么把手中这张房票收益最大化？ 来源美丽南岗 我们留意到，不少房票村民普遍面临着一种"幸福的烦恼"： 说实话，这些问题没有标准答案，但有一个底层逻辑必须先搞懂： 房票的最大价值除了能够原址回迁，还能有购入中心区房子的机会。如果从收租保值等角度考虑，简单的1:1置换观念，其实并不算最好的选择。 房票的优势，是从只能考虑本区域房源，转变为有机会选择地段更优的项目，只是这个"升级"，通常需要3:1甚至更高的兑换比例。 基于这个前提，有两种实际情况： 第一种，拿着黄埔的房票，1:1去换增城的面积。这不难理解，毕竟谁都想住得宽敞一点。 第二种，去选择地段更好、产品更优的房子。当然，这种选择自然要用商品房价值逻辑来谨慎比较。 确定了核心资产的方向，在具体的黄埔楼市中，怎么选才能不踩坑？ 我们调研了黄埔近十年的楼市数据，总结出了一套"房票兑现四大法则"。不管你最后买了哪里，这套逻辑都值得你反复推敲。 记住楼 ...

做了20年财经记者，我最清楚中长线赚钱的关键，就是别被短期涨跌带偏，抓核心逻辑。现在市场不是 普涨普跌，而是结构性机会，AI看硬科技、地产看核心资产、光伏看龙头整合、贵金属做对冲，茅台 这类消费股则要等基本面企稳。 你们觉得AI和光伏，哪个更值得中长线布局？评论区聊聊你的看法。我是帮主郑重，只分享有逻辑的 中长线干货，下期咱们深扒具体标的，不见不散～ 楼市这边更有意思，4个一线城市二手房前11个月卖了51.9万套，创了4年新高。这可不是短期炒作，而 是政策宽松后，置换链条通了，很多人卖旧房买新房，"量增—信心恢复—价稳"的良性循环正在形成。 对中长线来说，优质城市的核心房产和地产链里的龙头企业，值得多留个心眼。 光伏行业要变天了，30亿的多晶硅收储平台成立，第四次洗牌要来了。前几年硅料产能扩太多，价格从 30万跌到3万，全行业亏得厉害，现在头部企业联合起来整合产能，淘汰落后产能，这就像给行业"止 血"。中长线看，有成本和技术优势的硅料龙头，还有垂直一体化的企业，会在这轮整合中受益。 最后聊聊茅台，散瓶批价跌到1520元，两年跌了43%，经销商躺赢的日子过去了。说白了就是之前囤货 的太多，库存压顶，加上消费端有 ...

01 12月4日，三大指数涨跌不一，创业板指尾盘走强。摩尔线程12月5日将在科创板上市，相关概念股爆发，带动半导体主题ETF上涨，涨幅前 十的ETF中，有6只半导体相关ETF。 02 近期债市震荡，债券相关ETF成交活跃。12月4日，成交额前十的ETF中，7只为债券相关ETF。今日跌幅较大的30年国债相关ETF成交额较 大。科创债ETF成交持续活跃，12月1日以来，每天均有多只科创债ETF位列成交额前十名单。 03 核心资产吸金。12月3日，资金净流入居前的ETF中出现多只中证A500相关ETF、沪深300ETF等产品。 半导体相关ETF涨幅居前 12月4日，半导体产业链表现活跃。涨幅前十的ETF中有6只半导体相关ETF，其中，半导体设备ETF（561980）涨幅达3.63%，在所有A股 ETF中涨幅最高。 | 代码 | 简称 | 涨幅 (%) | | --- | --- | --- | | 159502.OF | 标普生物科技ETF | 3.85 | | 561980.OF | 半导体设备ETF | 3.63 | | 159559.OF | 机器人50ETF | 3.16 | | 588710.OF | 科 ...

01 12月1日，市场震荡拉升，沪指重返3900点上方。有色金属板块爆发，科技题材持续活跃，带动相关ETF上涨，涨幅前十的ETF中，有4 只有色、黄金相关ETF以及4只物联网相关ETF。 02 近期，债市持续震荡，债券相关ETF成交活跃。12月1日，成交额前十的ETF中，除1只短融ETF和2只货币ETF外，其余均为债券相关 ETF。科创债ETF成交持续活跃，4只科创债ETF成交额超90亿元。 03 核心资产迎来增量资金。11月28日，资金净流入居前的ETF中，出现上证50ETF（510050）、中证500ETF（510500）等产品。 有色、物联网相关ETF涨幅居前 12月1日，有色金属板块爆发。涨幅前十的ETF中4只为有色、黄金相关ETF，其中，黄金股票ETF基金涨超4%，在所有ETF中涨幅最 高。工业有色ETF涨近4%。 科技题材表现活跃，通信设备、物联网等相关ETF涨幅居前。涨幅居前的ETF中，有4只为物联网相关ETF。 对于今日大涨的有色金属板块，业内人士分析称，有色金属行业大涨的主要原因是，美联储降息预期升温导致流动性宽松预期增强，叠 加供给紧张和需求增长支撑价格上涨。 跌幅方面，12月1日，多只跨 ...

Group 1 - The current A-share bull market is part of a six-year global liquidity expansion driven by post-2020 monetary easing, with systemic revaluation of key assets such as gold, US tech stocks, and European/Japanese manufacturing [1][11] - The return of cross-border capital to China is expected to systematically reassess the competitive advantages of Chinese manufacturing, particularly in sectors like new energy, chemicals, and medical devices [2][12] - The A-share market is likely to experience volatility in 2026, with either a stagnation of the bull market or a "Davis Double Play" in consumer sectors, as external exports may not drive profits due to high base effects [3][13] Group 2 - The industrialization maturity phase in China has led to a bull market for core assets, driven by improved domestic consumption and the ability of manufacturing to generate national wealth through exports [4][14] - The recommendation for industry allocation focuses on a combination of "existing," "new," and "high" sectors, emphasizing non-ferrous metals, new consumption trends, and high-end manufacturing [5][14] Group 3 - The investment logic for China Hongqiao includes short-term price increases in electrolytic aluminum and long-term growth driven by integrated operations and high dividends [17][19] - For Luoyang Molybdenum, the investment rationale is based on the rising copper cycle and diversified product offerings, with a focus on sustainable growth [20][22] - Huafeng Aluminum is positioned for growth through high-end aluminum processing and international expansion, capitalizing on trends in the automotive sector [25][28] Group 4 - Nanjing Steel's strategy involves creating a fully integrated supply chain and exploring new growth points to stabilize returns on equity [29][32] - Dongfang Tower's investment logic is driven by rising prices of potassium chloride and phosphate rock, with ongoing capacity expansion [33][36] - Luxshare Precision is transitioning to an AI hardware manufacturer, benefiting from increased demand for computing power and AI models [37][40] Group 5 - Great Wall Motors is focusing on high-end SUVs and global expansion, with new model launches expected to drive sales [41][44] - Leap Motor is leveraging competitive pricing and differentiation in the domestic and overseas markets, with new models and subsidies supporting growth [45][48] - Heng Rui Pharmaceutical is advancing its clinical pipeline with over 100 innovative products, aiming for significant growth through international collaborations and new product approvals [49][51] Group 6 - Yifeng Pharmacy is expected to improve its market share through enhanced operational efficiency and strategic store adjustments [54][59] - Dongfang Electric is positioned to benefit from rising global demand for gas turbines, driven by AI-related power needs [60][63]

Core Viewpoint - The phase of broad increases in the innovative drug sector may be over, and the next two years will be a critical period for differentiation among innovative drug companies, making selective stock picking and focusing on true leaders a more suitable investment strategy [1] Group 1: Investment Strategy - The company will continue to focus on domestic commercialization and international expansion, prioritizing companies that excel in both areas rather than solely betting on business development (BD) transactions [1] - Valuations driven solely by BD are considered fragile, necessitating a careful assessment of associated risks [1] - The market tends to factor in potential total value (including milestone payments) into stock prices at the announcement of BD transactions, but the realization of milestone payments is uncertain and depends on clinical and regulatory success [1] Group 2: Sector Outlook - The company is optimistic about specific segments within innovative drugs, including Antibody-Drug Conjugates (ADC), multi-antibodies, cell and gene therapy, and autoimmune products [2] - Beyond innovative drugs, the company also sees potential in medical devices, Contract Research Organizations (CRO), and medical services [2] - The medical device sector is expected to experience significant growth in orders and inventory digestion due to increased procurement data amid a replacement trend [2] - The CRO sector is likely to benefit from the global shift towards research outsourcing, maintaining steady growth [2] - Economic recovery is anticipated to boost demand for medical services, particularly in high-end and specialized medical services [2]

Group 1 - The article emphasizes that a new cycle is quietly brewing amidst global monetary and fiscal easing, with smart capital positioning itself to seize opportunities in this new phase [1][3] - The Hong Kong luxury property market is showing signs of rebound and recovery, indicating strong signals from smart money that is strategically investing [2][6] - The current year is identified as the first year of "dual easing" in China, with key financial indicators like M1 gradually recovering, leading to a resurgence in property transactions in major cities [6][11] Group 2 - Data shows that in the first ten months, Shanghai accounted for 60% of luxury home transactions in China, highlighting its dominance in the high-end residential market [25] - The article notes that the core assets in major cities, particularly in Shanghai, are becoming increasingly scarce, which is driving smart capital to invest in these high-value properties [10][34] - The investment logic of high-net-worth individuals is based on the belief that core urban properties are valuable and worth holding, as they tend to appreciate over time [9][14] Group 3 - Historical data indicates that core urban properties have consistently outperformed overall market trends, with significant price increases observed in cities like London, Paris, and New York over the past decades [15][20] - The article highlights that despite economic fluctuations, core assets in major cities remain attractive to investors due to their inherent scarcity and high value [12][24] - The focus on prime locations is reiterated, with the article stating that only properties with unique, non-replicable attributes can withstand economic cycles and continue to appreciate [14][23] Group 4 - The article discusses the specific appeal of the Xuhui area in Shanghai, which is seen as a prime investment location due to its commercial vibrancy and concentration of high-net-worth individuals [26][29] - It mentions that the luxury market in Shanghai is characterized by intense competition, with developers investing significantly in product quality to attract discerning buyers [34][31] - The article concludes that smart capital is making informed decisions based on historical trends and current market conditions, positioning itself for future gains [35][36]

Group 1 - A-shares showed mixed performance in early trading, with the Shanghai Composite Index rebounding by 0.38% before noon, driven by gains in the banking and lithium sectors, while most technology and tourism sectors adjusted [1] - By midday, the CSI A500 Index rose by 0.1%, the CSI 300 Index increased by 0.3%, the ChiNext Index fell by 0.5%, and the STAR Market 50 Index declined by 0.6%, while the Hang Seng China Enterprises Index decreased by 0.1% [1] Group 2 - The ChiNext Index, which is tracked by the ChiNext ETF, consists of 100 stocks with high market capitalization and liquidity, with a significant proportion in strategic emerging industries, particularly in power equipment, communications, and electronics, which together account for nearly 60% [4] - The STAR Market 50 Index, tracked by the STAR Market 50 ETF, includes 50 stocks from the STAR Market with high market capitalization and liquidity, prominently featuring technology leaders, with semiconductors making up over 65% and combined with medical devices and software development, accounting for nearly 80% [4]

Core Viewpoint - The A-share market indices are trending upwards, with the MSCI China A50 Connect Index rising approximately 0.55%, led by major stocks such as Bank of China, Zhongji Xuchuang, and Industrial Fulian [1] Group 1: Market Performance - The MSCI China A50 Connect Index reflects the performance of core leading assets in the A-share market, showing a positive trend [1] - A50 ETF (159601) is closely tracking the MSCI China A50 Connect Index, highlighting its value proposition as it packages 50 leading stocks for investors [1] Group 2: Foreign Investment Outlook - Several foreign institutions have released outlook reports for 2026, collectively optimistic about the long-term investment value of the Chinese stock market [1] - UBS and Morgan Stanley have raised their target index levels for the Chinese market, indicating a bullish sentiment towards Chinese assets [1] - Foreign institutions are actively conducting research and increasing their positions in Chinese assets, demonstrating confidence in the market [1] Group 3: Index Characteristics - The MSCI China A50 Connect Index emphasizes liquidity and industry balance during its compilation, showcasing significant large-cap characteristics compared to other "beautiful 50" indices [1]